Myc Proto Oncogene Protein Market – Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, March 20, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Myc Proto Oncogene Protein – Pipeline Review, H1 2018”

Myc Proto Oncogene Protein  

Overview

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases.

It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3066579-myc-proto-oncogene-protein-transcription-factor-p64-or

Top Companies mentioned

Peptomyc SL

Phylogica Ltd

Sorrento Therapeutics Inc

Myc Proto Oncogene Protein Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Myc Proto Oncogene Protein    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myc Proto Oncogene Protein   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 6 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Myc Proto Oncogene Protein pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Myc Proto Oncogene Protein – Competitive Analysis

Key players are making innovative developments in Myc Proto Oncogene Protein industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Myc Proto Oncogene Protein.

The pipeline guide reviews pipeline therapeutics for Myc Proto Oncogene Protein by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myc Proto Oncogene Protein therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myc Proto Oncogene Protein therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Myc Proto Oncogene Protein.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3066579-myc-proto-oncogene-protein-transcription-factor-p64-or

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire